Wanbang Pharmaceutical announced that the cumulative deviation value of the closing price drop of the company's stock exceeded 30% for two consecutive trading days, which was an abnormal fluctuation. After self-inspection, there was no need to correct or supplement the information disclosed earlier by the company. No major undisclosed information affecting the stock price was discovered. The operation was normal recently, there were no major changes in the internal and external environment, the company and controlling shareholders, etc. had no undisclosed matters that should be disclosed, and the controlling shareholders did not trade the company's shares during the period of abnormal fluctuations. In addition, the company will disclose its semi-annual report on August 29. The impact of the June share acquisition on performance is yet to be verified, reminding investors to be aware of the risks.

Wanbang Pharmaceutical announced that the cumulative deviation value of the closing price drop of the company's stock exceeded 30% for two consecutive trading days, which was an abnormal fluctuation. After self-inspection, there was no need to correct or supplement the information disclosed earlier by the company. No major undisclosed information affecting the stock price was discovered. The operation was normal recently, there were no major changes in the internal and external environment, the company and controlling shareholders, etc. had no undisclosed matters that should be disclosed, and the controlling shareholders did not trade the company's shares during the period of abnormal fluctuations. In addition, the company will disclose its semi-annual report on August 29. The impact of the June share acquisition on performance is yet to be verified, reminding investors to be aware of the risks.